spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ThromboGenics 

 HSMN NewsFeed - 4 Mar 2014
ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA(R) in the US
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 3 Dec 2013
J-Code for ThromboGenics' JETREA to Become Effective January 1, 2014
Biopharmaceuticals Ophthalmology Reimbursement
 HSMN NewsFeed - 5 Sep 2013
ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 3 Sep 2013
Amakem Appoints Jean Marie Stassen as Vice President, Research and Development
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 2 Sep 2013
UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA(R) for Treatment of Vitreomacular Traction and Macular Hole
Biopharmaceuticals Ophthalmology Regulatory Reimbursement
 HSMN NewsFeed - 2 Aug 2013
Germany's IQWiG Confirms That ThromboGenics' JETREA(R) Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 Jun 2013
ThromboGenics' JETREA(R) Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 18 Jan 2013
ThromboGenics Receives Positive CHMP Opinion for JETREA(R)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 9 Jan 2013
BioInvent Recruits New Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2013
ThromboGenics Confirms JETREA(R) US Launch Date of Monday January 14th, 2013
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 18 Oct 2012
U.S. FDA Approves ThromboGenics' JETREA(R) (Ocriplasmin) for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 17 Apr 2012
ThromboGenics Resubmits BLA for Ocriplasmin With the FDA
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 16 Mar 2012
ThromboGenics Enters Into Commercialization Agreement for Ocriplasmin With Alcon Outside the United States
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Sep 2010
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Aug 2008
ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Aug 2008
Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Dec 2007
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
ThromboGenics
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.